Antidyskinetic properties of topiramate: a double-blind, placebo-controlled trial in patients with Parkinson's disease and levodopa-induced dyskinesias
ISRCTN | ISRCTN95151471 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN95151471 |
Secondary identifying numbers | 2007 Neuro 12 |
- Submission date
- 20/05/2008
- Registration date
- 02/07/2008
- Last edited
- 09/05/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Montague Silverdale
Scientific
Scientific
Salford Royal NHS Foundation Trust
Stott Lane
Salford
M6 8HD
United Kingdom
Phone | +44 1625 661782 |
---|---|
monty.silverdale@srft.nhs.uk |
Study information
Study design | Multicentre, randomised, double-blind, placebo-controlled, crossover study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet. |
Scientific title | Antidyskinetic properties of topiramate: a double-blind, placebo-controlled trial in patients with Parkinson's disease and levodopa-induced dyskinesias |
Study objectives | Levodopa therapy is effective for the motor symptoms of Parkinson's disease. However, around half of patients develop abnormal involuntary movements, or dyskinesia, after 4 - 6 years of treatment. Current treatment interventions for this are not satisfactory in all cases. Hypothesis: Topiramate administration will attenuate levodopa-induced dyskinesia in patients with Parkinson's disease (PD) without worsening parkinsonism. |
Ethics approval(s) | Leeds (West) Research Ethics Committee, 24/01/2008, ref: 07/H1307/205 |
Health condition(s) or problem(s) studied | Parkinson's disease and levodopa-induced dyskinesia |
Intervention | This is a randomised, crossover study. Topiramate group: start dose 25 mg/day orally (p.o.), to be up-titrated by 25 mg/day weekly to target dose of 100 mg/day in two divided doses. Participants to stay on maintenance dose for two weeks prior to assessment. Participants will attend having not taken usual morning medications, and response to these medications will then be assessed. Control: placebo capsules, identical in appearance. To be titrated on same schedule as topiramate. Following a two-week down-titration period, there will be a further two-week washout period before crossover. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Topiramate |
Primary outcome measure | Investigator-rated dyskinesia severity. To be scored by a blinded assessor from video recordings of participants, every 30 minutes for a total of 150 minutes. Dyskinesia to be rated at each time-point using a 5-point objective dyskinesia intensity rating scale, rating seven body parts (each limb, face, trunk and neck) with a maximum possible score of 28 at each time point. Timepoints of assessment: baseline (week 0), end of Arm 1 (week 6) and end of Arm 2 (week 16) |
Secondary outcome measures | 1. Investigator-rated parkinsonism. Unified Parkinson's Disease Rating Scale (UPDRS) part III to be assessed at 30-minute intervals during clinical assessment. Timepoints of assessment: week 0, 6 and 16. 2. Subject-rated dyskinesia severity: 2.1. Lang-Fahn Activities of Daily Living Dyskinesia Scale. Timepoints of assessment: week 0, 6, and 16. 2.2. Clinical Global Impression of change, assessed weekly during dose titration and at weeks 6 and 16 2.3. UPDRS Part IV. Timepoints of assessment: week 0, 6 and 16. 3. Effects on mood and activities of daily living: 3.1. UPDRS Part I, II. Timepoints of assessment: week 0, 6 and 16. 3.2. Geriatric Depression Scale-15. Timepoints of assessment: week 0, 2, 4, 6, 10, 12, 14 and 16. 4. Excessive daytime sleepiness: Epworth Sleepiness Scale. Timepoints of assessment: week 0, 2, 4, 6, 10, 12, 14 and 16. |
Overall study start date | 01/07/2008 |
Completion date | 01/01/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Other |
Sex | Both |
Target number of participants | 30 |
Key inclusion criteria | 1. Both males and females, no age limits 2. Patients with Parkinson's disease as defined by UK Parkinson's Disease Society Brain Bank criteria 3. Current use of levodopa, dose to be stable for one month prior to enrolment 4. Stable levodopa-induced dyskinesias |
Key exclusion criteria | 1. Hypersensitivity to topiramate or its excipients 2. Prior surgery for PD 3. Hoehn and Yahr score of 5 when "off" 4. Dementia 5. History of nephrolithiasis, renal impairment, liver disease, glaucoma 6. Pregnancy and breastfeeding 7. Premenopausal females and males not using adequate contraception 8. Use of other antiepileptic drugs, carbonic anhydrase inhibitors, metformin, digoxin or illicit drugs |
Date of first enrolment | 01/07/2008 |
Date of final enrolment | 01/01/2010 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Salford Royal NHS Foundation Trust
Salford
M6 8HD
United Kingdom
M6 8HD
United Kingdom
Sponsor information
Salford Royal NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Clinical Sciences Building
Stott Lane
Salford
M6 8HD
England
United Kingdom
Phone | +44 161 206 5137 |
---|---|
rachel.georgiu@manchester.ac.uk | |
Website | http://www.srht.nhs.uk |
https://ror.org/019j78370 |
Funders
Funder type
University/education
University of Manchester (UK)
Government organisation / Universities (academic only)
Government organisation / Universities (academic only)
- Alternative name(s)
- The University of Manchester, University of Manchester UK, University of Manchester in United Kingdom, UoM
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
09/05/2016: No publications found, verifying study status with principal investigator.